Novo nordisk a articles
-
Novo Nordisk beats profit estimates as sales of weight loss drug Wegovy more than double
Sales of popular weight loss drug Wegovy more than doubled to 9.38 billion kroner.
-
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.
-
Motley Fool Wealth Management LLC Lowers Position in Novo Nordisk A/S (NYSE:NVO)
Motley Fool Wealth Management LLC lowered its holdings in Novo Nordisk A/S (NYSE:NVO – Free Report) by 1.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 192,468 shares of the company’s stock after selling 2,372 shares during the period. Novo […]